home / stock / rfl / rfl news

RFL News and Press, Rafael Holdings Inc. Class B From 05/07/20

Stock Information
Company Name: Rafael Holdings Inc. Class B
Stock Symbol: RFL
Market: NYSE
Website: rafaelholdings.com
Menu
RFL RFL Quote RFL Short RFL News RFL Articles RFL Message Board
Get RFL Alerts

News, Short Squeeze, Breakout and More Instantly...
RFL - Rafael Pharmaceuticals Announces In Vivo Study to Evaluate the Effects of CPI-613® (Devimistat) in Combination with Azacitidine and Venetoclax on Acute Myeloid Leukemia Models

Cranbury, NJ, May 07, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced that it has entered into a research collaboration with a major medica...
RFL - Rafael Pharmaceuticals Enters into Research Collaboration with Roswell Park Comprehensive Cancer Center to Evaluate the Effects of CPI-613® (Devimistat) on Esophageal Cancer

Cranbury, NJ, May 05, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced that it has entered into a research collaboration with Roswell Park ...

RFL - MD Anderson Cancer Center Now Enrolling Patients in Rafael Pharmaceuticals' Phase 2 Clinical Trial of CPI-613® (devimistat) for Relapsed or Refractory Burkitt's Lymphoma/Leukemia

Cranbury, NJ, April 28, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced the expansion of its Phase 2 clinical trial of CPI-613® (devim...

RFL - Rafael Pharmaceuticals Receives Approvals to Open Trial Sites in India and Canada for Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (devimistat) in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)

Cranbury, NJ, April 23, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced that the Central Drugs Standard Control Organization (CDSCO),...
RFL - Rafael Pharmaceuticals Enrolls More Than 75% of Patients Needed for Pivotal Phase 3 Trial (AVENGER 500) of CPI-613®? (devimistat) for Patients with Metastatic Pancreatic Cancer

Cranbury, NJ, March 24, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced that it has enrolled more than 75% of the 500 patients needed for i...

RFL - Tracking Kahn Brothers Portfolio - Q4 2019 Update

This article is part of a series that provides an ongoing analysis of the changes made to Kahn Brothers’ 13F stock portfolio on a quarterly basis. It is based on Kahn Brothers’ regulatory 13F Form filed on 01/27/2020. Please visit our Tracking Kahn Brothers Portfolio series t...

RFL - LipoMedix Announces Publication of Positive Phase 1 Data for Promitil® (PL-MLP) in Research Journal Investigational New Drugs

JERUSALEM, Jan. 23, 2020 (GLOBE NEWSWIRE) -- LipoMedix , a clinical-stage, oncology-focused pharmaceutical company, involved in the development of innovative, safe and effective cancer therapy based on a pegylated liposomal drug delivery platform, today announced that Phase 1 data of Promi...
RFL - Rafael Pharmaceuticals Announces the Initiation of a Phase 1b/2 Clinical Trial of CPI-613® (devimistat) in Combination with Gemcitabine and Cisplatin in Patients with Biliary Tract Cancer

Cranbury, NJ, Jan. 21, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism -based therapeutics, announced today its collaboration with Michigan Medicine to proceed with a Phase...

RFL - Rafael Pharmaceuticals Crosses Halfway Enrollment Point in Pivotal Phase 3 Trial (AVENGER 500) of CPI-613®? (devimistat) for Patients with Metastatic Pancreatic Cancer

Cranbury, NJ, Jan. 14, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced that it has reached an enrollment milestone of more than 250 patient...

RFL - Barer Institute Announces Founding Board Members

NEWARK, N.J. , Jan. 13, 2020 /PRNewswire/ -- The Barer Institute, a collaborative cancer drug development initiative of Rafael Holdings, Inc. , (NYSE: RFL), today announced the slate of highly regarded scientific and business leaders that will serve as its founding Board of Director...
Previous 10 Next 10